Australia, like the rest of the world, is facing a silent but devastating health crisis: the rise of drug-resistant infections, often dubbed “superbugs.” Our current arsenal of antibiotics is rapidly becoming obsolete, creating a perilous gap between evolving microbes and the dwindling pipeline of new treatments. This growing disparity puts countless lives at risk, threatening to unravel decades of medical progress.
Currently, approximately one in every six bacterial infections is resistant to the antibiotics we rely on. Projections are stark: a significant analysis published in The Lancet estimates that antibiotic resistance could be responsible for nearly 170 million deaths globally within the next 25 years. The urgency to innovate and develop new antimicrobial medicines has never been greater.
The Challenge: A Dwindling Pipeline and Economic Hurdles
Antimicrobial resistance occurs when dangerous microorganisms, such as bacteria and fungi, develop the ability to withstand the medicines designed to kill them. Antibiotics have been a cornerstone of modern medicine, transforming previously lethal infections into treatable conditions. Without effective antibiotics, routine medical procedures like hip replacements and even childbirth could once again become life-threatening. Already, drug-resistant bacteria are claiming over a million lives annually worldwide.
This escalating crisis is not just a medical concern; it carries profound implications for national security. A future where antibiotics are ineffective leaves us alarmingly vulnerable to biological threats and other emergent dangers. Just like pandemics and natural disasters, the impact of antimicrobial resistance will be felt by both our defence forces and the wider civilian population.
The inherent nature of how antibiotics work presents a significant hurdle for drug development. Each time an antibiotic is used, any surviving microbes can mutate and adapt, fostering resistance for future encounters. This means that the efficacy of an antibiotic naturally diminishes over time with use, necessitating a prudent and judicious approach to their application.
While this careful usage strategy helps to slow resistance, it also creates a peculiar economic landscape for antibiotic development. Despite their immeasurable value in saving lives, the market for new antibiotics is surprisingly small. Companies investing in this research face immense difficulty in recouping their costs. Developing a single antibiotic can take over a decade and cost upwards of $1 billion. Astonishingly, one estimate suggests that the return on investment for developing an antibiotic can be a negative $50 million, making the odds heavily stacked against developers.
Consequently, many large biopharmaceutical companies have exited the antibiotic development arena. While smaller biotechnology firms continue to grapple with the challenge, many are struggling to survive. A handful of new antibiotics from these startups have gained FDA approval since 2017, but nearly every company involved has subsequently faced bankruptcy, abandoned their research, or been forced into acquisitions.
This market collapse is particularly concerning when considering the immense societal benefit that new antibiotics would provide. Researchers estimate that developing and improving access to novel antibiotics could save the Australian healthcare system billions of dollars annually by 2050.
A New Model for Antibiotic Innovation
To address this critical shortfall, a new paradigm for antibiotic development is desperately needed – one that offers financial certainty to drug developers, enabling them to bring these life-saving treatments to fruition. In the United States, a bipartisan group of legislators has put forward a potential solution in the form of the Pasteur Act, recently reintroduced in Congress.
This proposed legislation outlines a subscription-based model. Under this system, the federal government would enter into agreements with companies that successfully develop novel antimicrobials targeting the most threatening infections. This would ensure that healthcare professionals have access to these vital treatments, while the companies would receive a predictable revenue stream, moving away from the precarious reliance on sales volume. Crucially, patients would gain access to these essential, life-saving medications for the most dangerous infections.
The Stakes: Health, Economy, and Security
The decision by lawmakers to act on this pressing legislation is pivotal. Failure to pass measures like the Pasteur Act will jeopardise our nation’s health security, economic stability, and the lives of countless citizens.
With this vital legislation now under consideration, our politicians have a critical opportunity to finally equip Australia to face the growing health crisis of antimicrobial resistance. Taking decisive action now is essential to prevent the consequences of inaction from becoming irreversible. The time to prepare is now, before the silent threat of superbugs overwhelms our defences.
